查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1850406

核子医学影像设备市场（按产品、放射性药物、应用和最终用户划分）—2025-2032年全球预测

Nuclear Imaging Equipment Market by Product, Radiopharmaceuticals, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，核医影像设备市场规模将达到 95.5 亿美元，复合年增长率为 6.09%。

关键市场统计数据
基准年 2024 59.5亿美元
预计年份：2025年 62.9亿美元
预测年份 2032 95.5亿美元
复合年增长率 (%) 6.09%

本文简要概述了技术创新、商业压力和不断变化的临床需求如何重塑核子医学摄影造影设备的部署和应用。

核子医学扫描术诊断领域正处于曲折点，技术创新、不断变化的临床需求和政策环境正在再形成诊断和治疗路径。检测器材料、重建演算法和混合成像架构的进步提高了核医学检查的灵敏度和特异性，使临床医生能够更早发现病变并更详细地表征疾病的生物学特征。同时，放射性药物生产和分销网络的日益成熟，扩大了可用示踪剂的种类，从而拓展了临床适应症，并增加了对特定成像方式设备的需求。

儘管技术不断进步，但相关人员在采购决策、营运流程和资本配置方面仍面临日益复杂的挑战。影像服务供应商必须权衡对尖端PET和SPECT平台的投资与人员配备、试剂供应和报销框架等实际情况。因此，临床、营运和商业领导者需要基于证据的讯息，将仪器性能与临床影响和营运可行性联繫起来。本执行摘要总结了这些动态，重点关注结构性变化、监管和贸易影响、细分市场洞察、区域性考虑以及实用建议，旨在帮助决策者清晰、自信地应对近期市场格局。

模式融合、放射性药物多样化和人工智慧主导的分析将如何重新定义临床工作流程、商业模式和伙伴关係策略？

核子医学影像领域正经历着一场变革性的转变，这场转变由三个相互关联的因素所驱动：影像方式的融合、放射性药物的多样化以及计算技术的增强。 PET/CT 和 SPECT/CT 一体化平台实现了解剖结构与功能之间的无缝关联，从而提高了诊断的准确性和手术效率。同时，放射性药物套件也在不断扩展，纳入了靶向特异性更高的示踪剂以及能够将诊断与标靶治疗相结合的诊疗一体化药物组合，从而改变了影像中心和肿瘤诊所的临床路径和资金需求。

硬体和示踪剂的创新与人工智慧和定量分析的进步相辅相成，正在改变影像的重建、解读以及将其整合到临床决策中的方式。机器学习主导的降噪和病灶检测提高了有效通量并减少了重复检查，而标准化的定量指标则增强了对病患监测。监管机构正日益明确医疗设备器材软体（SaaS）的核准路径，促使供应商调整产品蓝图，转向检验的演算法组件。此外，供应链的韧性和本地化生产正在改变采购行为，并促进设备製造商、放射性药物製造商和服务机构之间的策略联盟。总而言之，这些转变正在创造一个格局：长期领先地位不仅取决于设备规格，还取决于临床价值、工作流程整合和生态系统协作。

评估2025年关税政策如何改变了核子医学影像设备相关人员的供应链采购行为和策略采购

2025年关税政策为核子成像生态系统带来了新的成本和物流复​​杂性，并对设备采购、备件库存和放射性药物供应链产生了连锁反应。进口影像处理组件和製造投入品关税的提高迫使供应商重新评估其全球采购布局，并加速了关于近岸组装、供应商多元化以及重新谈判长期供应商合约的讨论。重要的是，这些变化也影响临床医疗机构的资本规划，许多机构现在在进行设备更换和扩大决策时，会将更长的前置作业时间和更高的到岸成本考虑在内。

除了硬体之外，关税也影响了放射性药物耗材和专用硬体模组的流通，促使一些供应商整合物流，并寻求简化产品配置，以减少对受关税影响零件的依赖。为此，买家采取了多种应对策略，包括扩大服务协议范围以维持运作、为关键备件储备特定库存缓衝，以及更多地使用多年期采购协议以确保价格可预测性。政策主导的成本上涨也加速了对基于价值的采购模式的需求，在这种模式下，设备选择标准更注重吞吐量、试剂效率和可维护性，而不是主要规格参数。虽然关税造成了短期成本压力，但也催化了结构性转变，这些转变有可能透过区域化供应链网络和策略供应商伙伴关係来提高长期供应韧性。

产品类型情报揭示了放射性药物的临床用途和最终用户类型如何决定采购优先顺序和营运权衡。

按细分市场解读市场动态，可以揭示影响投资决策和实践设计的、产品、示踪剂、临床和终端用户方面的洞察。在产品架构方面，平面闪烁显像系统继续满足低复杂度诊断流程的需求，而正子断层扫描 (PET) 扫描仪则提供灵敏的功能性影像，这对于高阶肿瘤学和神经病学应用至关重要。单光子发射电脑断层扫描 ( SPECT) 扫描仪则介于两者之间，其中混合型 SPECT 影像系统透过 CT 配准扩展了诊断功能，而独立式 SPECT 平台则为优先考虑吞吐量的机构提供了经济高效的解决方案。这些产品差异影响着不同临床环境下的采购逻辑。

放射性药物的可用性和特性正产生类似的影响。氟代脱氧葡萄糖仍然是代谢成像的核心示踪剂，而镓-68在胜肽受体成像和新型诊疗一体化应用中的实用性，推动了临床对现场或区域发生器解决方案的需求。碘-131在已确立的治疗适应症中仍然具有重要意义，而Technetium-99m由于其良好的物理特性和广泛的分销渠道，继续支持各种常规闪烁扫描检查。在临床上，心臟病学和肿瘤学主导高端影像模式的使用，而神经病学和感染疾病诊断则需要专门的示踪剂和通讯协定。整形外科依赖更平面的SPECT技术进行标靶评估。诊断影像中心优先考虑吞吐量和多重模式影像能力，以满足转诊网路的需求；医院和诊所需要与更广泛的电子健康记录和介入手术室整合；而研究机构则需要能够支援临床实验示踪剂和快速通讯协定变更的灵活平台。选择与示踪剂策略、临床适应症和最终用户操作限制一致的产品，对于优化资本回报和临床疗效至关重要。

从区域视角分析美洲、欧洲、中东和非洲以及亚太地区的法律规范、报销机制和生产布局如何驱动不同的应用和伙伴关係选择。

区域动态正在影响美洲、欧洲、中东和非洲以及亚太地区的应用曲线、监管复杂性和供应链选择，每个地区都呈现出独特的部署条件和战略机会。在美洲，成熟的报销框架和密集的转诊网络有利于先进PET平台和混合系统的快速普及，而活跃的临床研究活动则推动了新型示踪剂和诊疗一体化工作流程的早期应用。另一方面，一些公共医疗机构的资金限制促使他们选择资金筹措方案和管理服务协议，以降低前期支出，同时确保能够获得最新的影像处理技术。

欧洲、中东和非洲的监管和报销环境各不相同。一些国家实行集中式的卫生技术评估流程和严格的价值验证计划，而新兴市场则对经济高效的SPECT和平面成像系统表现出需求。这种区域差异也为平台标准化创造了机会，从而支持跨国临床试验和跨境服务模式。在亚太地区，诊断基础设施的快速扩张、对本地放射性药物生产的投资以及政府对国内生产的大力支持，正在加速PET和SPECT系统的应用。这些市场的特点是临床需求量大，并且对包括远端监测和人工智慧驱动的工作流程优化在内的整合服务模式有着强烈的需求。在每个区域内，软体和放射性药物核准方面的监管趋势、不断变化的报销政策以及本地生产能力，将继续推动差异化的应用模式和伙伴关係模式。

领先的供应商和服务供应商如何整合硬体、软体和放射药学伙伴关係关係，以创建稳健的经常性收入模式和竞争优势

核子医学影像生态系统中的主要企业正在围绕整合硬体、放射性药物和软体主导的临床工作流程的综合价值主张调整其策略。供应商更加重视可维护性和正常运作时间提案，因为他们认识到设备生命週期经济性和营运连续性对医院和诊断中心至关重要。与物流製造商和物流供应商建立策略合作伙伴关係已成为确保端到端解决方案的关键策略，该解决方案将示踪剂的可用性与扫描仪的部署联繫起来，从而缩短患者运作时间并简化临床排班。

同时，众多公司正大力投资可扩展的软体平台，以提供定量成像、决策支援和远端监测服务。这些服务旨在创造稳定的收入来源，并支援与吞吐量、诊断准确性和治疗方案有效性挂钩的绩效合约。为了吸引资源有限的买家，各公司也尝试灵活的商业模式，例如按扫描付费合约和基于订阅的高级分析服务。最后，成功的公司优先考虑监管策略和临床证据的生成，并与学术中心合作，检验新的示踪剂、重建演算法和诊疗一体化路径，从而在竞争激烈的采购过程中凸显其差异化提案主张。

为供应商、製造商和投资者提供可操作的策略重点，以增强供应链韧性、加速软体应用，并将资本部署与临床价值挂钩。

产业领导者应优先采取策略行动，以平衡短期韧性与基于价值的个人化医疗的长期定位。首先，应实现采购管道多元化并加强与供应商的关係，以减轻关税造成的供应中断。对于关键零件，应选择性地进行近岸外包，同时保持专用零件和耗材的多来源选择。其次，应加快软体和分析技术的投资，以提高扫描器的使用率和诊断效率。检验的人工智慧工具和定量报告系统可以显着降低营运成本并提高临床疗效，从而为差异化采购提供有力支援。

第三，我们将与物流生产商和物流供应商建立策略伙伴关係，使示踪剂的供应与临床计划相匹配，并实现一体化服务交付。第四，我们将采用灵活的商业模式，降低购买者的资金门槛，例如管理服务协议、基于绩效的定价以及延长设备生命週期的模组化升级方案。第五，我们将透过实证实践和卫生经济学示范计划，积极与监管机构和支付方沟通，以确保获得有利的报销，并简化软体功能的核准流程。这些措施将共同支持永续成长，并改善不同医疗机构获得先进诊断和治疗工作流程的机会。

采用严谨的混合方法研究途径，结合专家访谈、工具性分析、监管研究和供应链图谱分析，以检验策略见解和假设。

本执行报告的研究采用多学科方法，结合一手和二手研究，建构了可靠的依证。一手研究包括对临床终端使用者、采购负责人和服务工程师进行结构化访谈，以了解营运限制、培训需求和运作优先事项。这些定性见解与设备规格、临床试验结果和监管核准趋势的技术分析相结合，以评估不同平台类型的能力差异。供应链图谱确定了组件和示踪剂分销的关键节点，情境分析则探讨了政策变化和关税相关成本波动的影响。

二次研究利用同行评审的临床文献、监管文件、专利资料库以及来自製造商和医疗保健机构的公开信息，检验有关技术性能和临床效用的提案。在适用情况下，根据临床指引更新和已发表的比较效果研究评估了示踪剂的具体价值主张。透过反覆的同侪检验以及记录资料来源和研究假设，确保了调查方法的严谨性。这使得我们能够从整体观点进行策略决策，而无需依赖专有或专有的预测结果。

对整合临床路径供应​​弹性及检验的软体产品如何决定核子医学摄影成像市场长期领导地位进行全面分析

摘要：核医影像市场正从以设备为中心的市场转向一体化的临床生态系统转变，其长期成功取决于放射性药物的供应、软体智慧和供应链韧性。混合成像和演算法重构的技术进步拓展了诊断能力，同时也提高了营运整合和临床检验的难度。关税主导的复杂性给采购和物流带来了新的短期压力，但也促使企业进行策略调整，从长远来看，这可能会形成更具韧性的供应架构和更本地化的能力。

因此，决策者应根据临床应用案例、营运限制和当地监管实际情况做出投资选择。透过优先选择兼具诊断准确性、工作流程效率和服务稳定性的解决方案，医疗机构可以在降低整体拥有成本的同时改善患者预后。随着治疗路径越来越依赖精准的分子影像和诊疗一体化，专注于整合产品、灵活的商业性模式和检验的软体组件的製造商和投资者将占据有利地位，从而获得持久价值。未来的道路需要协作的生态系统、主导的产品设计以及能够将技术前景转化为可衡量的临床影响的实用商业模式。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 人工智慧增强影像重建技术在数位SPECT/CT系统中的应用日益广泛
  • 增加针对个人化癌症治疗的诊疗整合放射性核种研发的投资
  • 将小型迴旋加速器模组整合到核子成像实验室中，以缓解同位素供应限制。
  • 全球主要市场放射性药物核准途径的监管协调
  • 开发用于偏远地区和紧急情况下现场核子医学扫描术诊断的可携式伽马摄影机
  • α粒子成像剂的出现及其在肿瘤高解析度分子特性中的应用
  • 影像设备製造商与放射性药物製造商合作，以提高物流效率
  • 扩展混合型PET/MRI扫描仪，以实现同时进行代谢和软组织成像
  • 为每位患者实施先进的剂量测定软体，以实现精确的辐射剂量管理。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 核子医学影像设备市场（依产品划分）

  • 平面闪烁成像系统
  • 正子断层扫描（PET）扫描仪
  • 单光子发射电脑断层扫描（SPECT）扫描仪
    • 混合式SPECT影像系统
    • 独立式SPECT影像系统

9. 核子医学影像设备市场 - 放射性药物

  • 氟代脱氧葡萄糖（FDG）
  • 镓-68
  • 碘-131
  • Technetium-99m

第十章 核子医学影像设备市场（依应用领域划分）

  • 心臟病学
  • 感染疾病的诊断
  • 神经病学
  • 肿瘤学
  • 整形外科

第十一章 核子医学影像设备市场（依最终用户划分）

  • 诊断影像中心
  • 医院和诊所
  • 研究所

第十二章 核医影像设备市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 核医影像设备市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国核子医学影像设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Absolute Imaging Inc.
    • Advanced Accelerator Applications SA by Norvatis
    • Agfa-Gevaert NV
    • Bayer AG
    • Bozlu Holding AS
    • Bracco Imaging SpA
    • Canon Medical Systems Corporation
    • CMR Naviscan Corporation
    • Cubresa Inc.
    • DDD-Diagnostic A/S
    • Digirad Corporation
    • Edge Medical Solutions Private Limited
    • GE HealthCare Technologies Inc.
    • Koninklijke Philips NV
    • Mediso Ltd.
    • MR Solutions Ltd.
    • Neusoft Medical Systems Co., Ltd.
    • PerkinElmer Inc.
    • Revvity Inc
    • Rigaku Corporation
    • Shimadzu Corporation
    • Siemens AG
    • Surgiceye GmbH
    • United Imaging Healthcare Co., Ltd.
Product Code: MRR-50124643717F

The Nuclear Imaging Equipment Market is projected to grow by USD 9.55 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.95 billion
Estimated Year [2025] USD 6.29 billion
Forecast Year [2032] USD 9.55 billion
CAGR (%) 6.09%

A concise framing of how technological innovation operational pressures and evolving clinical needs are reshaping nuclear imaging equipment deployment and adoption

The field of nuclear imaging equipment stands at an inflection point where technological innovation, evolving clinical needs, and shifting policy environments converge to reshape diagnostic and therapeutic pathways. Advances in detector materials, reconstruction algorithms, and hybrid imaging architectures have elevated both the sensitivity and specificity of nuclear scans, enabling clinicians to detect pathology earlier and to characterize disease biology with greater granularity. At the same time, the maturation of radiopharmaceutical manufacturing and distribution networks has expanded the portfolio of available tracers, which in turn broadens clinical indications and drives demand for modality-specific instrumentation.

Despite these technical gains, stakeholders face increasing complexity in procurement decisions, operational workflows, and capital allocation. Imaging service providers must balance investments in cutting-edge PET and SPECT platforms against the realities of staffing, reagent availability, and reimbursement frameworks. Consequentially, leaders across clinical, operational, and commercial functions require evidence-based intelligence that links device capability to clinical impact and operational feasibility. This executive summary synthesizes those dynamics, highlighting structural shifts, regulatory and trade influences, segmentation-level insights, regional considerations, and practical recommendations that equip decision-makers to navigate the near-term landscape with clarity and confidence.

How modality convergence radiopharmaceutical diversification and AI-driven analytics are collectively redefining clinical workflows commercial models and partnership strategies

The nuclear imaging landscape is undergoing transformative shifts driven by three interrelated vectors: modality convergence, radiopharmaceutical diversification, and computational augmentation. Hybridization of imaging systems has moved beyond single-point upgrades to become a dominant architectural principle, with integrated PET/CT and SPECT/CT platforms enabling seamless anatomical-functional correlation that improves diagnostic confidence and procedural efficiency. Concurrently, the radiopharmaceutical toolkit has expanded to incorporate tracers with higher target specificity and theranostic pairings that link diagnosis to targeted therapy, thereby altering clinical pathways and capital requirements for imaging centers and oncology clinics.

Complementing hardware and tracer innovation, advances in artificial intelligence and quantitative analytics are changing how images are reconstructed, interpreted, and integrated into clinical decision-making. Machine learning-driven denoising and lesion detection improve effective throughput and reduce repeat scans, while standardized quantitative metrics enhance longitudinal patient monitoring. Regulatory agencies are increasingly defining pathways for software-as-a-medical-device approvals, prompting vendors to reorient product roadmaps toward validated algorithmic components. Moreover, supply chain resiliency and localized manufacturing initiatives are shifting procurement behavior, encouraging strategic partnerships between equipment manufacturers, radiopharmaceutical producers, and service organizations. Taken together, these shifts create a landscape in which clinical value, workflow integration, and ecosystem partnerships determine long-term leadership rather than device specifications alone.

Assessment of how tariff policy enacted in 2025 has altered supply chains procurement behavior and strategic sourcing among nuclear imaging equipment stakeholders

Tariff policy implemented in 2025 introduced a new layer of cost and logistical complexity for the nuclear imaging ecosystem, with ramifications reverberating across device procurement, spare-parts inventory, and radiopharmaceutical supply chains. Increased duties on imported imaging components and manufacturing inputs have pressured vendors to reassess global sourcing footprints, accelerating conversations about nearshoring assembly, diversifying supplier bases, and renegotiating long-term supplier agreements. Importantly, this dynamic has also influenced capital planning horizons for clinical providers, many of whom are now factoring extended lead times and higher landed costs into replacement and expansion decisions.

Beyond hardware, tariffs have affected the movement of radiopharmaceutical-related consumables and specialized hardware modules, prompting some suppliers to consolidate logistics and to pursue simplified product configurations that reduce dependency on tariffed components. In response, purchasers have adopted a mix of mitigation strategies including expanded service contracts to preserve uptime, selective inventory buffers for critical spare parts, and greater use of multi-year procurement agreements to lock in pricing predictability. Policy-driven cost inflation has also accelerated demand for value-based procurement models, wherein equipment selection criteria emphasize throughput, reagent efficiency, and serviceability over headline specifications. While tariffs introduce short-term cost pressures, they have also catalyzed structural shifts that may improve long-term supply resilience through localized supply networks and strategic vendor partnerships.

Segment-aware intelligence revealing how product categories radiopharmaceutical classes clinical applications and end-user types jointly determine procurement priorities and operational trade-offs

Segment-focused interpretation of market dynamics reveals distinct product, tracer, clinical, and end-user realities that influence investment decisions and operational design. Within product architecture, planar scintigraphy imaging systems continue to serve lower-complexity diagnostic workflows, while positron emission tomography scanners deliver high-sensitivity functional imaging essential for advanced oncology and neurology applications. Single Photon Emission Computed Tomography scanners occupy a middle ground where hybrid SPECT imaging systems extend diagnostic capability through CT co-registration and stand-alone SPECT platforms offer cost-effective solutions for centers prioritizing throughput. These product distinctions drive procurement logic across diverse clinical settings.

Radiopharmaceutical availability and characteristics exert a parallel influence. Fluorodeoxyglucose remains a central workhorse tracer for metabolic imaging, whereas Gallium-68's utility in peptide receptor imaging and novel theranostic applications has increased clinical demand for on-site or regional generator solutions. Iodine-131 retains relevance for established therapeutic indications, and Technetium-99m continues to underpin a broad array of routine scintigraphic studies due to its favorable physical properties and wide distribution infrastructure. Clinically, cardiology and oncology dominate utilization patterns for high-end modalities, with neurology and infectious disease diagnosis requiring specialized tracers and protocols. Orthopedics relies more on planar and SPECT techniques for targeted evaluations. End-user distinctions matter: diagnostic imaging centers prioritize throughput and multi-modality capability to serve referral networks, hospitals and clinics require integration with broader electronic medical records and interventional suites, and research institutes demand flexible platforms that support investigational tracers and rapid protocol changes. Aligning product selection with tracer strategy, clinical indication, and end-user operational constraints is essential to optimize returns on capital and clinical impact.

A regional lens on how regulatory frameworks reimbursement dynamics and manufacturing footprints across Americas EMEA and Asia-Pacific drive differentiated adoption and partnership choices

Regional dynamics shape adoption curves, regulatory complexity, and supply-chain choices across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each geography presenting unique deployment conditions and strategic opportunities. In the Americas, mature reimbursement frameworks and high-density referral networks favor rapid uptake of advanced PET platforms and hybrid systems, while strong clinical research activity drives early adoption of novel tracers and theranostic workflows. Conversely, capital constraints at some public facilities encourage financing options and managed service agreements that reduce upfront expenditure while preserving access to modern imaging capability.

Europe, Middle East & Africa present a heterogeneous set of regulatory and reimbursement environments where centralized health technology assessment processes in some jurisdictions drive rigorous value demonstration, and in others, emerging markets exhibit demand for cost-efficient SPECT and planar systems. The region's diversity also creates opportunities for platform standardization that supports multinational clinical trials and cross-border service models. In the Asia-Pacific region, rapid expansion of diagnostic infrastructure, investments in local radiopharmaceutical production, and strong government interest in domestic manufacturing have accelerated deployment of both PET and SPECT systems. These markets are characterized by a combination of high-volume clinical demand and an appetite for integrated service models, including remote monitoring and AI-enabled workflow optimization. Across regions, regulatory pathways for software and radiopharmaceutical approval, reimbursement policy shifts, and local manufacturing capabilities will continue to drive differentiated adoption patterns and partnership models.

How major vendors and service providers are integrating hardware software and radiopharmaceutical partnerships to create resilient recurring-revenue models and competitive differentiation

Leading organizations in the nuclear imaging equipment ecosystem are realigning strategies around integrated value propositions that combine hardware, radiopharmaceutical enablement, and software-driven clinical workflows. Vendors are placing greater emphasis on serviceability and uptime guarantees, recognizing that equipment lifecycle economics and operational continuity are decisive factors for hospitals and diagnostic centers. Strategic alliances with radiopharmaceutical manufacturers and logistics providers have become frontline tactics to secure end-to-end solutions that link tracer availability with scanner deployment, thereby reducing patient wait times and simplifying clinical scheduling.

In parallel, a cohort of companies is investing heavily in scalable software platforms to deliver quantitative imaging, decision support, and remote monitoring services. These offerings are designed to create sticky revenue streams and to enable performance-based contracts tied to throughput, diagnostic accuracy, or treatment planning efficacy. Companies are also experimenting with flexible commercial models including pay-per-scan arrangements and subscription-based access to premium analytics, which appeal to resource-constrained buyers. Finally, successful players prioritize regulatory strategy and clinical evidence generation, partnering with academic centers to validate new tracers, reconstruction algorithms, and theranostic pathways that support differentiated value propositions in competitive procurement processes.

Actionable strategic priorities for providers manufacturers and investors to enhance supply resilience accelerate software adoption and link capital deployment to clinical value

Industry leaders should prioritize a triage of strategic actions that balance near-term resilience with long-term positioning for value-based, personalized care. First, diversify sourcing and strengthen supplier relationships to mitigate tariff-induced supply disruptions; engage in selective nearshoring for critical components while maintaining multi-sourced options for specialized parts and consumables. Second, accelerate investments in software and analytics that improve scanner utilization and diagnostic throughput; validated AI tools and quantitative reporting systems can materially reduce operational costs and improve clinical impact, thereby supporting differentiated procurement justifications.

Third, cultivate strategic partnerships with radiopharmaceutical manufacturers and logistics providers to ensure tracer availability aligns with clinical schedules and to enable integrated service offerings. Fourth, adopt flexible commercial models that reduce capital barriers for buyers, such as managed service contracts, outcome-linked pricing, and modular upgrade paths that extend device lifecycles. Fifth, engage proactively with regulators and payers through robust evidence generation and health economic demonstration projects to secure favorable reimbursement and to streamline approvals for software-enabled features. Collectively, these actions will support sustainable growth while improving access to advanced diagnostic and theranostic workflows for diverse care settings.

A rigorous mixed-methods research approach combining expert interviews device analytics regulatory review and supply-chain mapping to validate strategic insights and assumptions

The research underpinning this executive synthesis combined a multidisciplinary approach incorporating primary and secondary inputs to create a robust evidence base. Primary research included structured interviews with clinical end-users, procurement leaders, and service engineers to capture operational constraints, training needs, and uptime priorities. These qualitative insights were triangulated with technical analyses of device specifications, clinical trial outcomes, and regulatory approval trends to assess capability differentials among platform types. Supply chain mapping identified critical nodes for components and tracer distribution, while scenario analysis explored sensitivity to policy shifts and tariff-related cost movements.

Secondary research drew on peer-reviewed clinical literature, regulatory filings, patent databases, and public disclosures from manufacturers and healthcare providers to validate assertions regarding technology performance and clinical utility. Where applicable, clinical guideline updates and published comparative effectiveness studies informed assessments of tracer-specific value propositions. Throughout the research process, methodological rigor was maintained through iterative validation with subject-matter experts and by documenting data provenance and analytical assumptions. The outcome is a synthesized perspective designed to inform strategic decision-making without relying on proprietary or proprietary forecasting outputs.

Synthesis of how integrated clinical pathways supply resilience and validated software offerings will determine long-term leadership in nuclear imaging equipment markets

In summary, the nuclear imaging equipment landscape is evolving from a device-centric market into an integrated clinical ecosystem where radiopharmaceutical availability, software intelligence, and supply-chain resilience determine long-term success. Technological advances in hybrid imaging and algorithmic reconstruction have expanded diagnostic capability while also raising the bar for operational integration and clinical validation. Tariff-driven complexities introduced new short-term pressures on procurement and logistics, but they also incentivized strategic adjustments that may yield more resilient supply architectures and localized capability over time.

Decision-makers should therefore align investment choices with clinical use cases, operational constraints, and regional regulatory realities. By privileging solutions that combine diagnostic accuracy, workflow efficiency, and service robustness, providers can deliver improved patient outcomes while containing total cost of ownership. Manufacturers and investors that focus on integrated offerings, flexible commercial arrangements, and validated software components will be positioned to capture enduring value as care pathways increasingly depend on precise molecular imaging and theranostic alignment. The path forward requires collaborative ecosystems, evidence-driven product design, and pragmatic commercial models that translate technological promise into measurable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of digital SPECT/CT systems with AI-enhanced image reconstruction
  • 5.2. Rising investment in theranostic radionuclide development for personalized cancer treatment
  • 5.3. Integration of compact cyclotron modules within nuclear imaging labs to reduce isotope supply constraints
  • 5.4. Regulatory harmonization of radiopharmaceutical approval pathways across key global markets
  • 5.5. Development of portable gamma cameras for point-of-care nuclear imaging in remote and emergency settings
  • 5.6. Emergence of alpha-particle imaging agents for high-resolution molecular characterization of tumors
  • 5.7. Collaboration between imaging equipment manufacturers and radiopharmacies for streamlined logistics
  • 5.8. Expansion of hybrid PET/MRI scanners to leverage simultaneous metabolic and soft tissue imaging
  • 5.9. Implementation of advanced dosimetry software for precise patient-specific radiation dose management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Imaging Equipment Market, by Product

  • 8.1. Planar Scintigraphy Imaging Systems
  • 8.2. Positron Emission Tomography (PET) Scanners
  • 8.3. Single Photon Emission Computed Tomography (SPECT) Scanners
    • 8.3.1. Hybrid SPECT Imaging Systems
    • 8.3.2. Standalone SPECT Imaging Systems

9. Nuclear Imaging Equipment Market, by Radiopharmaceuticals

  • 9.1. Fluorodeoxyglucose (FDG)
  • 9.2. Gallium-68
  • 9.3. Iodine-131
  • 9.4. Technetium-99m

10. Nuclear Imaging Equipment Market, by Application

  • 10.1. Cardiology
  • 10.2. Infectious Disease Diagnosis
  • 10.3. Neurology
  • 10.4. Oncology
  • 10.5. Orthopedics

11. Nuclear Imaging Equipment Market, by End-User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals & Clinics
  • 11.3. Research Institutes

12. Nuclear Imaging Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nuclear Imaging Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nuclear Imaging Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Absolute Imaging Inc.
    • 15.3.2. Advanced Accelerator Applications S.A. by Norvatis
    • 15.3.3. Agfa-Gevaert N.V
    • 15.3.4. Bayer AG
    • 15.3.5. Bozlu Holding A. S.
    • 15.3.6. Bracco Imaging S.p.A.
    • 15.3.7. Canon Medical Systems Corporation
    • 15.3.8. CMR Naviscan Corporation
    • 15.3.9. Cubresa Inc.
    • 15.3.10. DDD-Diagnostic A/S
    • 15.3.11. Digirad Corporation
    • 15.3.12. Edge Medical Solutions Private Limited
    • 15.3.13. GE HealthCare Technologies Inc.
    • 15.3.14. Koninklijke Philips N.V.
    • 15.3.15. Mediso Ltd.
    • 15.3.16. MR Solutions Ltd.
    • 15.3.17. Neusoft Medical Systems Co., Ltd.
    • 15.3.18. PerkinElmer Inc.
    • 15.3.19. Revvity Inc
    • 15.3.20. Rigaku Corporation
    • 15.3.21. Shimadzu Corporation
    • 15.3.22. Siemens AG
    • 15.3.23. Surgiceye GmbH
    • 15.3.24. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NUCLEAR IMAGING EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NUCLEAR IMAGING EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEAR IMAGING EQUIPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PLANAR SCINTIGRAPHY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HYBRID SPECT IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY STANDALONE SPECT IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY FLUORODEOXYGLUCOSE (FDG), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY IODINE-131, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 229. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 232. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 233. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 234. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 235. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 236. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 237. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 240. GCC NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 265. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 270. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 271. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 272. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 273. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 276. G7 NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 277. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 280. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 281. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 282. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 283. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 284. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 285. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 288. NATO NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SCANNERS, 2025-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NUCLEAR IMAGING EQUIPMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)